Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate
-
- Yoshiya Tanaka
- University of Occupational and Environmental Health , Japan, Kitakyushu, Japan
-
- Tsutomu Takeuchi
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan
-
- Hisashi Yamanaka
- Rheumatology, Sanno Medical Center , Tokyo, Japan
-
- Toshihiro Nanki
- Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine , Tokyo, Japan
-
- Hisanori Umehara
- Division of Rheumatology and Immunology, Nagahama City Hospital , Shiga, Japan
-
- Nobuyuki Yasuda
- KAN Research Institute, Inc. , Kobe, Japan
-
- Fumitoshi Tago
- Eisai Co. Ltd , Tokyo, Japan
-
- Yasumi Kitahara
- Eisai Co. Ltd , Tokyo, Japan
-
- Makoto Kawakubo
- Eisai Co. Ltd , Tokyo, Japan
-
- Kentaro Torii
- Eisai Co. Ltd , Tokyo, Japan
-
- Seiichiro Hojo
- Eisai Co. Ltd , Tokyo, Japan
-
- Tetsu Kawano
- KAN Research Institute, Inc. , Kobe, Japan
-
- Toshio Imai
- KAN Research Institute, Inc. , Kobe, Japan
抄録
<jats:title>ABSTRACT</jats:title> <jats:sec> <jats:title>Objectives</jats:title> <jats:p>To evaluate the long-term safety and efficacy of E6011, a humanized anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Active RA patients with an inadequate response to MTX were randomly assigned to the E6011 or placebo group and received the study drug subcutaneously every 2 weeks during a 24-week double-blind study period. Subjects who completed evaluations at Week 24 were rolled over into the extension phase and received open-label E6011 (200 or 400 mg) every 2 weeks until Week 102. The safety analysis was conducted up to Week 104, and the efficacy analysis was conducted up to Week 84.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>A total of 169 subjects completed the double-blind treatment phase and were rolled over into the extension phase. In total, 167 (98.8%) subjects experienced any adverse events, and the incidence of treatment-related adverse events was 56.2%. The American College of Rheumatology 20 response rates were observed between 40 and 70% during the extension phase.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>E6011 was safe and well tolerated with no notable safety concerns up to 102 weeks in RA patients with an inadequate response to MTX.</jats:p> </jats:sec>
収録刊行物
-
- Modern Rheumatology
-
Modern Rheumatology 34 (1), 37-44, 2023-01-21
Oxford University Press (OUP)
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1360861711969151744
-
- ISSN
- 14397609
- 14397595
-
- データソース種別
-
- Crossref